[Switzerland changes from U-40 to U-100 insulin]

Area of Science:

• Endocrinology
• Pharmacology
• Public Health

Context:

• Switzerland predominantly uses U-40 insulin, but U-100 insulin is emerging with pen injectors.
• The coexistence of multiple insulin concentrations (U-40 and U-100) poses a significant risk of medication errors.
• International experience highlights the dangers associated with varied insulin concentrations.

Purpose:

• To standardize insulin concentrations in Switzerland by transitioning exclusively to U-100 insulin.
• To mitigate the high risk of severe dosage errors associated with multiple available insulin concentrations.
• To address the logistical and medical considerations of this nationwide insulin standardization initiative.

Summary:

• A planned transition from U-40 and U-100 to exclusively U-100 insulin in Switzerland (Oct 1988-Mar 1989) aims to enhance patient safety.
• A survey revealed approximately 60% of Swiss doctors and patients with insulin-dependent diabetes mellitus (IDDM) support the change, with 40% neutral or opposed.
• The study discusses the pros, cons, logistical challenges, and potential pharmacological differences of U-100 insulin, emphasizing the need for medical supervision and an information campaign.

Impact:

• The standardization to U-100 insulin is expected to significantly reduce medication errors and improve patient safety in Switzerland.
• Successful implementation requires careful medical supervision for all patients and a comprehensive information campaign for healthcare professionals and patients.
• This initiative addresses a critical public health concern in diabetes management by simplifying insulin dosing and reducing confusion.